ExodusPoint Capital Management’s ProQR Therapeutics PRQR Stock Holding History

ExodusPoint Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,700	Closed	-$71K	–	2712
2021 Q1	$71K	Sell	10,700 -20,402	-66%	-$104K	﹤0.01%	2006
2020 Q4	$131K	Buy	+31,102	New	+$131K	﹤0.01%	1801

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ExodusPoint Capital Management's PRQR Position: Q2 2021 in Review

ExodusPoint Capital Management sold out of ProQR Therapeutics (PRQR) in Q2 2021, closing a stake of 10,700 shares — an estimated $71K sold.

ExodusPoint Capital Management first reported a position in PRQR in Q4 2020 and held it in 2 quarters. The position peaked at $131K in Q4 2020. 63 funds tracked by Wall St. Rank hold PRQR as of Q2 2021.

ExodusPoint Capital Management reported no remaining ProQR Therapeutics position as of Q2 2021 after selling out during the quarter.
ExodusPoint Capital Management sold 10,700 ProQR Therapeutics shares in Q2 2021, an estimated $71K.
ExodusPoint Capital Management first reported a position in ProQR Therapeutics in Q4 2020 and held it in 2 quarters.
ExodusPoint Capital Management's ProQR Therapeutics position peaked at $131K in Q4 2020.
63 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2021.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.